natgillin/translations-raw huggingface dataset:
IOA, like other hormonal contraceptives, does not protect against HIV infection (AIDS) or any other sexually transmitted disease.
Tako kot druga hormonska kontracepcijska sredstva tudi zdravilo IOA ne varuje pred okužbo z virusom HIV (AIDS) ali katero drugo spolno prenosljivo boleznijo.
iodinated contrast agents or alcohol-containing medicines
jodirana kontrastna sredstva ali zdravila, ki vsebujejo alkohol;
iodine contrast media (agents used for imaging examinations). arthritis medicines.
jodirana kontrastna sredstva (sredstva, ki jih uporabljajo pri slikovnih preiskavah), zdravila za artritis.
iodine contrast media (agents used for imaging examinations);
jodiranih kontrastnih sredstev (sredstev, ki jih uporabljajo pri slikovnih preiskavah);
Iodine salts and/or levothyroxine.
jodovih soli in/ali levotiroksina.
Ioflupane (123I)
Ioflupan (123I)
Ioflupane (123I) is cleared rapidly from the blood after intravenous injection; only 5% of the administered activity remains in whole blood at 5 minutes post-injection.
Ioflupan (123I) se po intravenskem injiciranju hitro očisti iz krvi; 5 minut po injiciranju ostane v krvnem obtoku le 5 % aktivnosti.
iol/
orgestimat
Ion exchange resins
kontrastnih sredstev rehidrirati.
Ion exchange resins Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol.
Holestiramin in holestipol zmanjšujeta absorpcijo tiazidnih diuretikov, vključno s hidroklorotiazidom.
ION-1 was a randomised, open-label study that evaluated 12 and 24 weeks of treatment with ledipasvir/sofosbuvir with or without ribavirin in 865 treatment-naïve patients with genotype 1 CHC including those with cirrhosis (randomised 1:1:1:1).
ION-1 je bila randomizirana, odprta študija, ki je ocenila 12- in 24-tedensko zdravljenje z ledipasvirjem/sofosbuvirjem z ribavirinom ali brez njega pri 865 predhodno nezdravljenih bolnikih s CHC genotipa 1, vključno s tistimi s cirozo (randomiziranih v razmerju 1:1:1:1).
Ionisation, beam formation and acceleration all occur in the source, magnetic deflection takes place in the flight tube and detection takes place in the collector.
Ionizacija, tvorba žarka in pospešek potekajo v viru, magnetni odklon poteka v cevi in detekcija v kolektorju.
IONSYS 40 micrograms per dose transdermal system
IONSYS 40 mikrogramov na odmerek transdermalni sistem
IONSYS 40 micrograms per dose transdermal system Fentanyl
IONSYS 40 mikrogramov na odmerek transdermalni sistem fentanil
IONSYS DEVICE
PRIPOMOČEK IONSYS
IONSYS is a transdermal system and is made up of an electronic controller (the top housing) and a drug unit (the red bottom housing).
IONSYS je transdermalni sistem, sestavljen iz elektronskega upravljalnika (zgornji del ohišja) in zdravilne enote (rdeči spodnji del ohišja).
IONSYS is designed so that you can’t use too much, provided that only you operate it, and that only you use it when you need pain relief.
Sistem IONSYS je zasnovan tako, da ne morete uporabiti preveč zdravila, vendar ga morate upravljati sami in samo, kadar potrebujete lajšanje bolečin.
IONSYS is ready to be used again and you may start another dose at any time you need it.
Sistem IONSYS je takrat pripravljen za ponovno uporabo in sprožite lahko nov odmerek, kadar koli ga boste potrebovali.
IONSYS is restricted to hospital use only.
Sistem IONSYS se lahko uporablja samo v bolnišnicah.
IONSYS is used in hospital only.
Zdravilo IONSYS se uporablja samo v bolnišnicah.
IONSYS should also not be placed on skin on which topical medicines have been applied.
Ne sme se namestiti na kožne predele, na katerih so bila uporabljena zdravila za topikalno uporabo.
IONSYS should be removed before a magnetic resonance imaging (MRI) procedure, cardioversion, defibrillation, X-ray, CT scan or diathermy is undertaken.
Pred slikanjem z magnetno resonanco (MRI), rentgenom ali računalniško tomografijo in kardioverzijo, defibrilacijo ali diatermijo je treba sistem IONSYS odstraniti.
IONSYS should be removed prior to certain procedures such as cardioversion (electrical current used to restore normal heart rhythm), defibrillation (electric shock given to the heart) or diathermy (electrical current used in physical therapy or surgery).
Sistem IONSYS je treba odstraniti pred nekaterimi postopki, npr. kardioverzijo (električni tok, ki se uporablja za ponovno vzpostavitev normalnega srčnega ritma), defibrilacijo (električni šok za srce) ali diatermijo (električni tok, ki se uporablja pri fizioterapiji ali operacijah).
IONSYS should be used with caution in patients with hearing impairment who might not be able to hear the audible signals from the system.
Zdravilo IONSYS je treba uporabljati previdno pri bolnikih z okvaro sluha, ki morda ne bodo slišali zvočnih signalov sistema.
IONSYS should be used with caution in patients with paralytic ileus.
Pri bolnikih s paralitičnim ileusom je treba zdravilo IONSYS uporabljati previdno.
IONSYS should not be placed on abnormal skin sites, such as scars, burns, tattoos, etc.
Zdravilo IONSYS se ne sme namestiti na nenormalna mesta na koži, kot so brazgotine, opekline, tetovaže ipd.
IONSYS Troubleshooting
Odpravljanje težav s sistemom IONSYS
IONSYS was also evaluated in four active-control trials (predominantly female (65%), Caucasian (85%), with a mean age of 55 years (range, 18-91 years), and primarily comprised of surgeries including lower abdominal and orthopedic bone procedures) using a standard intravenous patient controlled analgesia (PCA) morphine regimen as the comparator.
Zdravilo IONSYS so ocenili tudi v štirih z zdravilno učinkovino nadzorovanih preskušanjih (pretežno pri ženskah (65 %), bele rase (85 %), s povprečno starostjo 55 let (razpon 18–91 let), večinoma po kirurških posegih na spodnjem delu trebuha in ortopedskih posegih), kjer so za primerjalno učinkovino uporabili standardni režim intravenske analgezije z morfinom, ki jo nadzoruje bolnik (PCA).
IONSYS will ignore any button presses during the 10-minute dosing period.
V 10-minutnem obdobju odmerjanja sistem IONSYS ne bo upošteval dodatnih pritiskov gumba.
IONSYS will then shut down and will not deliver any further doses.
Sistem IONSYS se bo nato izklopil in ne bo dovedel nadaljnjih odmerkov.
IONSYS with food, drink and alcohol
Zdravilo IONSYS skupaj s hrano, pijačo in alkoholom
IOP was measured in ‘millimetres of mercury’ (mmHg).
Očesni tlak se meri v „milimetrih živega srebra“ (mmHg).
IPD
2,1
Ipilimumab 3 mg/kg every
3 mg/kg na 3 tedne
Ipilimumab clearance increased with increasing body weight and with increasing LDH at baseline; however, no dose adjustment is required for elevated LDH or body weight after administration on a mg/kg basis.
Očistek ipilimumaba se je povečeval z naraščanjem telesne mase in naraščanjem vrednosti LDH v izhodišču, vendar pa odmerka glede na zvišane vrednosti LDH ali večjo telesno maso glede na uporabo zdravila na osnovi mg/kg ni treba prilagajati.
Ipilimumab has been designed to attach to and block the activity of a protein called CTLA-4 that is found on the surface of T cells, a type of white blood cell.
Ipilimumab je bil zasnovan tako, da se veže na beljakovino, imenovano CTLA-4, ki jo najdemo na površini limfocitov T (vrste belih krvnih telesc), in prepreči njeno delovanje.
Ipilimumab is a fully human anti-CTLA-4 monoclonal antibody (IgG1κ) produced in Chinese hamster ovary cells by recombinant DNA technology.
Ipilimumab je popolnoma humano monoklonsko protitelo (IgG1κ) proti CTLA-4, pridobljeno s tehnologijo rekombinantne DNA na ovarijskih celicah kitajskega hrčka.
Ipilimumab is associated with serious immune-related gastrointestinal reactions.
Uporaba ipilimumaba je bila povezana s pojavom resnih imunsko pogojenih neželenih učinkov v prebavilih.
Ipilimumab is associated with serious immune-related gastrointestinal reactions.
Uporaba ipilimumaba je povezana s pojavom resnih imunsko pogojenih neželenih učinkov v prebavilih.
Ipilimumab is associated with serious skin adverse reactions that may be immune-related.
Uporaba ipilimumaba je bila povezana s pojavom resnih neželenih učinkov na kožo, ki bi lahko bili imunsko pogojeni.
Ipilimumab is used to treat advanced melanoma (a type of skin cancer) in adults.
Ipilimumab uporabljamo za zdravljenje napredovalega melanoma (vrsta kožnega raka) pri odraslih.
Ipilimumab may selectively deplete T- regulatory cells at the tumour site, leading to an increase in the intratumoral T-effector/ T-regulatory cell ratio which drives tumour cell death.
Ipilimumab lahko selektivno zmanjša količino regulatornih celic T na mestu tumorja, s čimer se poveča razmerje med efektorskimi celicami T in regulatornimi celicami T znotraj tumorja, kar povzroči odmrtje tumorskih celic.
Ipilimumab must be permanently discontinued in patients with severe (Grade 3 or 4) diarrhoea or colitis (see section 4.2), and systemic high-dose intravenous corticosteroid therapy should be initiated immediately. (In clinical trials, methylprednisolone 2 mg/kg/day has been used).
Pri bolnikih s hudo drisko (stopnja 3 ali 4) ali kolitisom je treba zdravljenje z ipilimumabom trajno ukiniti (glejte poglavje 4.2) in nemudoma uvesti sistemsko zdravljenje z visokimi odmerki intravenskih kortikosteroidov (v kliničnih preskušanjih so uporabili metilprednizolon v odmerku 2 mg/kg/dan).
Ipilimumab-specific management guidelines for immune-related adverse reactions are described below.
V nadaljevanju so opisane za ipilimumab specifične smernice za ukrepanje v primeru pojava imunsko pogojenih neželenih učinkov.
Ipreziv 20 mg tablets azilsartan medoxomil
Ipreziv 20 mg tablete medoksomilazilsartanat
IPREZIV 20 MG TABLETS IPREZIV 40 MG TABLETS IPREZIV 80 MG TABLETS azilsartan medoxomil
Ipreziv 20 mg tablete Ipreziv 40 mg tablete Ipreziv 80 mg tablete medoksomilazilsartanat
Ipreziv 40 mg tablets azilsartan medoxomil
Ipreziv 40 mg tablete medoksomilazilsartanat
Ipreziv 80 mg tablets azilsartan medoxomil
Ipreziv 80 mg tablete medoksomilazilsartanat
Ipreziv are white round tablets debossed “ASL” on one side and either “20”, “40” or “80” on the other.
Zdravilo Ipreziv so bele, okrogle tablete z vtisnjeno oznako “ASL” na eni in številko “20”, “40” ali “80” na drugi strani.
Ipreziv at doses of 20, 40 or 80 mg has been evaluated for safety in clinical studies in patients treated for up to 56 weeks.
Varnost zdravila Ipreziv v odmerkih po 20, 40 ali 80 mg je bilo opredeljena s kliničnimi študijami pri bolnikih v trajanju do 56 tednov.
Ipreziv azilsartan medoxomil
Ipreziv medoksomilazilsartanat
Ipreziv blocks this effect so that the blood vessels relax, which helps lower your blood pressure.
Zdravilo Ipreziv preprečuje ta vpliv, krvne žile se sprostijo in to prispeva k znižanju krvnega tlaka.
Ipreziv is for oral use and may be taken with or without food (see section 5.2).
Zdravilo Ipreziv se jemlje peroralno, s hrano ali brez nje (glejte poglavje 5.2).
Ipreziv is indicated for the treatment of essential hypertension in adults.
Zdravilo Ipreziv je indicirano za zdravljenje esencialne hipertenzije pri odraslih.
Ipreziv is unlikely to have an effect on driving or using machines.
Zdravilo Ipreziv verjetno ne bo imelo vpliva na vožnjo ali upravljanje strojev.
Ipsen Pharma Lietuvos filialas 9-ojo Forto 47
Ipsen Pharma Lietuvos filialas
Ipsen Pharma S.A.
Ipsen Pharma, S.A.
IPSS is a rating of the patient’s symptoms such as the inability to empty the bladder, and the urge to urinate repeatedly or to strain while urinating.
IPSS je ocena bolnikovih simptomov, kot so nezmožnost praznjenja mehurja, potreba po pogostem mokrenju ali napenjanje med mokrenjem.
IR = incremental recovery; AUC = area under the factor IX activity time curve; CL = body weight adjusted clearance; Elimination t1/2 = Elimination half-life
IR = povrnitev aktivnosti; AUC = površina pod krivuljo aktivnosti faktorja IX v odvnisnosti od časa; CL = očistek, prilagojen na telesno maso; t1/2 izločanja = razpolovni čas izločanja
Irbesartan / Hydrochlorothiazide Teva
Irbesartan/hidroklorotiazid Teva
Irbesartan 300 mg film-coated tablets are white to off white capsule shaped, film coated tablet.
Irbesartan Teva 300 mg filmsko obložene tablete: bele do belkaste filmsko obložene tablete v obliki kapsule.
Irbesartan AUC and Cmax values were also somewhat greater in elderly subjects (≥ 65 years) than those of young subjects (18 - 40 years).
Vrednosti AUC in Cmax irbesartana so bile pri starejših osebah (≥65 let) nekoliko večje kot pri mlajših (18-40 let).
Irbesartan AUC and Cmax values were also somewhat greater in oldersubjects (≥ 65 years) than those of young subjects (18 - 40 years).
Vrednosti AUC in Cmax irbesartana so bile pri starejših osebah (≥65 let) nekoliko večje kot pri mlajših (18-40 let).
Irbesartan AUC and Cmax values were also somewhat greater in oldersubjects (≥ 65 years) than those of young subjects (18-40 years).
Vrednosti AUC in Cmax irbesartana so bile pri starejših osebah (≥65 let) nekoliko večje kot pri mlajših (18-40 let).
Irbesartan AUC and Cmax values were also somewhat greater in oldersubjects (≥ 65 years) than those of young subjects (18-40 years).
Vrednosti AUC in Cmax za irbesartan sta pri starejših osebah (≥ 65 let) nekoliko večji kot pri mlajših (18 do 40 let).
Irbesartan BMS 150 mg film-coated tablets are supplied in blister packs of 14, 28, 56, 84 or 98 film- coated tablets.
Irbesartan BMS 150 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 56, 84 ali 98 filmsko obloženimi tabletami.
Irbesartan BMS 150 mg film-coated tablets irbesartan
Irbesartan BMS 150 mg filmsko obložene tablete irbesartan
Irbesartan BMS 150 mg film-coated tablets.
Irbesartan BMS 150 mg filmsko obložene tablete.
Irbesartan BMS 150 mg tablets irbesartan
Irbesartan BMS 150 mg tablete irbesartan
Irbesartan BMS 150 mg tablets.
Irbesartan BMS 150 mg tablete
Irbesartan BMS 300 mg film-coated tablets are supplied in blister packs of 14, 28, 56, 84 or 98 film- coated tablets.
Irbesartan BMS 300 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 56, 84 ali 98 filmsko obloženimi tabletami.
Irbesartan BMS 300 mg film-coated tablets irbesartan
Irbesartan BMS 300 mg filmsko obložene tablete irbesartan
Irbesartan BMS 300 mg film-coated tablets.
Irbesartan BMS 300 mg filmsko obložene tablete.
Irbesartan BMS 300 mg tablets irbesartan
Irbesartan BMS 300 mg tablete irbesartan
Irbesartan BMS 300 mg tablets.
Irbesartan BMS 300 mg tablete
Irbesartan BMS 75 mg film-coated tablets are supplied in blister packs of 14, 28, 56, 84 or 98 film- coated tablets.
Irbesartan BMS 75 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 56, 84 ali 98 filmsko obloženimi tabletami.
Irbesartan BMS 75 mg film-coated tablets irbesartan
Irbesartan BMS 75 mg filmsko obložene tablete irbesartan
Irbesartan BMS 75 mg film-coated tablets.
Irbesartan BMS 75 mg filmsko obložene tablete.
Irbesartan BMS 75 mg tablets irbesartan
Irbesartan BMS 75 mg tablete irbesartan
Irbesartan BMS 75 mg tablets.
Irbesartan BMS 75 mg tablete
Irbesartan BMS can be taken with or without food.
Zdravilo Irbesartan BMS lahko jemljete s hrano ali brez nje.
Irbesartan BMS contains lactose.
Zdravilo Irbesartan BMS vsebuje laktozo.
Irbesartan BMS is for oral use.
Zdravilo Irbesartan BMS je potrebno zaužiti.
Irbesartan BMS is used
Zdravilo Irbesartan BMS uporabljamo:
Irbesartan BMS should not be given to children under 18 years of age.
Otroci in mladostniki, mlajši od 18 let, zdravila Irbesartan BMS ne smejo jemati.
Irbesartan BMS slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Pri bolnikih z visokim krvnim tlakom in sladkorno boleznijo tipa 2 zdravilo Irbesartan BMS upočasni pešanje delovanja ledvic.
Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg.
Farmakokinetika irbesartana v odmerku 10 do 600 mg je linearna in odvisna od odmerka.
Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg.
Irbesartan kaže linearno in z odmerkom sorazmerno farmakokinetiko v razponu odmerkov 10 do 600 mg.
Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg.
Irbesartan kaže linearno in z odmerkom sorazmerno farmakokinetiko v razponu odmerkov od 10 do 600 mg.
Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducingthe first signs of parental toxicity (see section 5.3).
Irbesartan ni vplival na plodnost podgan in njihovih potomcev v odmerkih, ki so povzročili prve znake toksičnih učinkov pri starših (glejte poglavje 5.3).
Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg filmsko obložene tablete irbesartan/hidroklorotiazid
Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg film-coated tablets.
Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg filmsko obložene tablete
Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
Zdravilo Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg je namenjeno bolnikom, pri katerih se zvišan krvni tlak med zdravljenjem samo s hidroklorotiazidom ali samo s 150 mg irbesartana ni dovolj znižal.
Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg tablete irbesartan/hidroklorotiazid
Irbesartan Hydrochlorothiazide BMS 150 mg/12.5 mg tablets.
Irbesartan Hydrochlorothiazide BMS 150 mg/12,5 mg tablete
Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg filmsko obložene tablete irbesartan/hidroklorotiazid
Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg film-coated tablets.
Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg filmsko obložene tablete
Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg tablete irbesartan/hidroklorotiazid
Irbesartan Hydrochlorothiazide BMS 300 mg/12.5 mg tablets.
Irbesartan Hydrochlorothiazide BMS 300 mg/12,5 mg tablete
Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg film-coated tablets irbesartan/hydrochlorothiazide
Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg filmsko obložene tablete irbesartan/hidroklorotiazid
Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg film-coated tablets.
Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg filmsko obložene tablete
Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg tablets irbesartan/hydrochlorothiazide
Irbesartan Hydrochlorothiazide BMS 300 mg/25 mg tablete irbesartan/hidroklorotiazid
Irbesartan Hydrochlorothiazide BMS can be taken with or without food.
Zdravilo Irbesartan Hydrochlorothiazide BMS lahko jemljete skupaj s hrano ali brez nje.
Irbesartan Hydrochlorothiazide BMS should not be given to children under 18 years of age.
Otroci in mladostniki, mlajši od 18 let, zdravila Irbesartan Hydrochlorothiazide BMS ne smejo jemati.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg film-coated tablets.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg filmsko obložene tablete
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
Zdravilo Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg je namenjeno bolnikom, pri katerih se zvišan krvni tlak med zdravljenjem samo s hidroklorotiazidom ali samo s 150 mg irbesartana ni dovolj znižal.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg film-coated tablets.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg filmsko obložene tablete
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg.
Zdravilo Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg je namenjeno bolnikom, pri katerih se krvni tlak med zdravljenjem s 300 mg irbesartana ali z zdravilom Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg ni dovolj znižal.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg film-coated tablets.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg filmsko obložene tablete
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg may be administered in patients insufficiently controlled by Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg.
Zdravilo Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg je namenjeno bolnikom, pri katerih se krvni tlak med zdravljenjem z zdravilom Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg ni dovolj znižal.
Irbesartan Hydrochlorothiazide Zentiva can be taken with or without food.
Zdravilo Irbesartan Hydrochlorothiazide Zentiva lahko jemljete skupaj s hrano ali brez nje.
Irbesartan Hydrochlorothiazide Zentiva is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Zdravilo Irbesartan Hydrochlorothiazide Zentiva je kombinacija irbesartana, antagonista angiotenzina II, in tiazidnega diuretika hidroklorotiazida.
Irbesartan Hydrochlorothiazide Zentiva is for oral use.
Zdravilo Irbesartan Hydrochlorothiazide Zentiva je potrebno zaužiti.
Irbesartan Hydrochlorothiazide Zentiva is unlikely to affect your ability to drive or use machines.
Možnost, da bi zdravilo Irbesartan Hydrochlorothiazide Zentiva vplivalo na sposobnost za upravljanje vozil in strojev je majhna.
Irbesartan Hydrochlorothiazide Zentiva should not be given to children under 18 years of age.
Otroci, mlajši od 18 let, zdravila Irbesartan Hydrochlorothiazide Zentiva ne smejo jemati.
Irbesartan Hydrochlorothiazide Zentiva should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.3).
Zdravilo Irbesartan Hydrochlorothiazide Zentiva se pri bolnikih s hudo ledvično okvaro (očistek kreatinina < 30 ml/min) ne sme uporabljati (glejte poglavje 4.3).
Irbesartan Hydrochlorothiazide Zentiva with food and drink
Zdravilo Irbesartan Hydrochlorothiazide Zentiva skupaj s hrano in pijačo
Irbesartan is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II.
Irbesartan je „antagonist receptorjev angiotenzina II“, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
Irbesartan is not removed by haemodialysis.
Irbesartan se s hemodializo ne izloči iz organizma.
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all- cause mortality.
Irbesartan je pomembno znižal tveganje za primarno povezan izid podvojitve serumskega kreatinina, zadnje faze ledvične bolezni (ESRD) in celokupne smrtnosti.
Irbesartan Teva 150 mg film-coated tablets Irbesartan
Irbesartan Teva 150 mg filmsko obložene tablete irbesartan
Irbesartan Teva 300 mg film-coated tablets Irbesartan
Irbesartan Teva 300 mg filmsko obložene tablete irbesartan
Irbesartan Teva is a ‘generic medicine’.
Irbesartan Teva je „generično zdravilo“.
Irbesartan Teva is available in pack sizes of 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 and 56 x 1 film coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-peroforated calendar blisters.
Zdravilo Irbesartan Teva je na voljo v pakiranjih po 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 in 100 filmsko obloženih tablet v pretisnih omotih; velikosti pakiranj po 50 x 1 in 56 x 1 filmsko obložena tableta v pretisnih omotih za enkratno odmerjanje in velikost pakiranja po 28 filmsko obloženih tablet v koledarskem pretisnem omotu.